Issue Date: October 5, 2009
J&J, Crucell Sign Antibody Deal
In a bid to increase its vaccines presence, Johnson & Johnson will pay roughly $440 million for an 18% stake in Dutch biotechnology firm Crucell. The companies are also collaborating to develop a universal monoclonal antibody product to treat and prevent all influenza A strains, including the novel 2009 H1N1 and avian H5N1 viruses. Crucell will be tasked with developing influenza antibodies it has already discovered through Phase IIa, along with . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society